Advanced search
Publication Cover
OncoImmunology Volume 1, 2012 - Issue 2
Submit an article Journal homepage
408
Views
4
CrossRef citations to date
0
Altmetric
Author's View

Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment

Alessandro Poggi Unit of Molecular Oncology and Angiogenesis; San Martino Hospital-National Institute for Cancer Research; University of Genoa; Genoa, ItalyCorrespondence[email protected] [email protected]
&
Maria Raffaella Zocchi Division of Immunology; Transplants and Infectious Diseases; Scientific Institute San Raffaele; Milan, ItalyCorrespondence[email protected] [email protected]
Pages 214-216 | Published online: 01 Mar 2012

References

  • Hochhaus A, O’Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukaemia. Leukemia 2009; 23:1054 - 61; http://dx.doi.org/10.1038/leu.2009.38; PMID: 19282833
  • Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8:1018 - 29; http://dx.doi.org/10.1016/S1470-2045(07)70342-X; PMID: 17976612
  • Smyth MJ. Imatinib Mesylate – Uncovering a fast track to adaptive immunity. N Engl J Med 2006; 354:2282 - 4; http://dx.doi.org/10.1056/NEJMcibr061878; PMID: 16723621
  • Catellani S, Pierri I, Gobbi M, Poggi A, Zocchi MR. Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia. PLoS One 2011. PLoS ONE 2011; 6:e18925; http://dx.doi.org/10.1371/journal.pone.0018925; PMID: 21533122
  • Martin F, Kearney JF. B1 cells: similarities and differences with other B cell subsets. Curr Opin Immunol 2001; 13:195 - 201; http://dx.doi.org/10.1016/S0952-7915(00)00204-1; PMID: 11228413
  • Schwartz-Albiez R, Laban S, Eichmueller S, Kirschfink M. Cytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy?. Autoimmun Rev 2008; 7:491 - 5; http://dx.doi.org/10.1016/j.autrev.2008.03.012; PMID: 18558368
  • Schaumann DH, Tuischer J, Ebell W, Manz RA, Lauster R. VCAM-1 positive stromal cells from human bone marrow producing cytokines for B lineage progenitors and for plasma cells: SDF-1, flt3L and BAFF. Mol Immunol 2007; 44:1606 - 12; http://dx.doi.org/10.1016/j.molimm.2006.08.021; PMID: 17067679
  • Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukaemia through reversal of abnormally increased proliferation. Blood 2002; 99:3792 - 800; http://dx.doi.org/10.1182/blood.V99.10.3792; PMID: 11986238
  • Tibullo D, Giallongo C, La Cava P, Beretta S, Stagno F, Chiarenza A, et al. Effects of imatinib mesylate in osteoblastogenesis. Exp Hematol 2009; 37:461 - 8; http://dx.doi.org/10.1016/j.exphem.2008.12.008; PMID: 19302920
  • Dürig J, Rosenthal C, Elmaagacli A, Heyworth C, Halfmeyer K, Kasper C, et al. Biological effects of stroma-derived factor-1 alpha on normal and CML CD34+ haemopoietic cells. Leukemia 2000; 14:1652 - 60; http://dx.doi.org/10.1038/sj.leu.2401875; PMID: 10995013

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.